Stockreport

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Ltd. - Ordinary Shares  (WVE) 
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am Check Earnings Report
PDF Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with lo [Read more]